A post by @FirstSquawk on X.
US REGULATORS WARN GLP-1 DRUGS CARRY POSSIBLE RARE BLINDNESS RISK – WSJ
@FirstSquawk on X
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
US regulators have flagged a possible rare blindness risk associated with GLP-1 drugs, the class of diabetes and weight-loss medications that includes Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound, according to a Wall Street Journal report. The warning matters because GLP-1 treatments have become among the industry's biggest revenue drivers, underpinning the market values of both Novo Nordisk and Eli Lilly. Watch for label updates, any regulator-requested studies, and whether prescribing patterns or sales guidance shift in response.
Muhabbit's AI wrote this summary of @FirstSquawk's post in its own words. It can get details wrong, so read the post on X.
Named in this story
GLP-1 drugs, US regulators, WSJ